

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



New Ray Medicine
新銳醫藥

New Ray Medicine International Holding Limited

新銳醫藥國際控股有限公司

(Incorporated in Bermuda with limited liability)

(Stock Code: 6108)

PROPOSED ADOPTION OF NEW BYE-LAWS

This announcement is made by New Ray Medicine International Holding Limited (“**Company**”, together with its subsidiaries as the “**Group**”) pursuant to Rule 13.51(1) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (“**Listing Rules**”) in relation to the proposed amendments to the existing bye-laws of the Company (“**Bye-laws**”).

The board (“**Board**”) of directors (“**Directors**”) of the Company proposes to make certain amendments to the Bye-laws (the “**Proposed Amendments**”) in order to, amongst others, (i) bring the Bye-laws to be in line with the latest legal and regulatory requirements, including the amendments made to Appendix 3 to the Listing Rules which took effect on 1 January 2022 (“**New Bye-laws**”); and (ii) incorporate certain housekeeping amendments. In view of the Proposed Amendments, the Board proposes to adopt the New Bye-laws in substitution for, and to the exclusion of, the Bye-laws.

A circular containing, among other matters, an explanation of the effect of the Proposed Amendments and the full terms of the Proposed Amendments, together with the notice of the forthcoming annual general meeting of the Company (“**AGM**”) and the proxy form, will be despatched to the shareholders of the Company (“**Shareholders**”) on 28 April 2023.

The proposed adoption of the New Bye-laws is subject to the approval of the Shareholders by way of a special resolution at the AGM, and will become effective upon the approval by the Shareholders at the AGM.

On behalf of the Board

New Ray Medicine International Holding Limited

Wang Qiuqin

Chairman, Chief Executive Officer and Executive Director

Hong Kong, 27 April 2023

As at the date of this announcement, the executive Directors are Ms. Wang Qiuqin, Mr. Huo Zhihong, Mr. Chu Xueping and Ms. Zhou Wan; and the independent non-executive Directors are Mr. Leung Chi Kin, Ms. Li Sin Ming, Ivy and Mr. Sy Lai Yin, Sunny.